The role of incomplete fatty acid β-oxidation in the development of cardiac insulin resistance

Cardiac Energy Metabolism in Health and Disease

Volumn , Issue , 2014, Pages 221-234

  Ussher, John R ^a  

^a MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Cardiac lipotoxicity; Cardiomyopathy; Ceramide; Diacylglycerol; Fatty acid oxidation; Incomplete fatty acid oxidation; Insulin resistance; Obesity; Triacylglycerol; Type 2 diabetes

Indexed keywords

EID: 84980529649     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4939-1227-8_14     Document Type: Chapter

References (65)

1. Ussher JR, Lopaschuk GD (2006) Clinical implications of energetic problems in cardiovascular disease. Heart Metab 32:9-17
2. Jaswal JS, Keung W, Wang W, et al (2011) Targeting fatty acid and carbohydrate oxidation-a novel therapeutic intervention in the ischemic and failing heart. Biochim Biophys Acta 1813:1333-1350
3. Lopaschuk GD, Ussher JR, Folmes CD, et al (2010) Myocardial fatty acid metabolism in health and disease. Physiol Rev 90:207-258
4. Dyck JR, Cheng JF, Stanley WC, et al (2004) Malonyl coenzyme a decarboxylase inhibition protects the ischemic heart by inhibiting fatty acid oxidation and stimulating glucose oxidation. Circ Res 94:e78-e84
5. Dyck JR, Hopkins TA, Bonnet S, et al (2006) Absence of malonyl coenzyme A decarboxylase in mice increases cardiac glucose oxidation and protects the heart from ischemic injury. Circulation 114:1721-1728
6. Liu Q, Docherty JC, Rendell JC, et al (2002) High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation. J Am Coll Cardiol 39:718-725
7. Masoud WG, Ussher JR, Wang W, et al (2013) Failing mouse hearts utilize energy inefficiently and benefit from improved coupling of glycolysis and glucose oxidation. Cardiovasc Res. doi: 10.1093/cvr/cvt216
8. Mori J, Basu R, McLean BA, et al (2012) Agonist-induced hypertrophy and diastolic dysfunction are associated with selective reduction in glucose oxidation: a metabolic contribution to heart failure with normal ejection fraction. Circ Heart Fail 5:493-503
9. Ussher JR, Koves TR, Jaswal JS, et al (2009) Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase. Diabetes 58:1766-1775
10. Ussher JR, Wang W, Gandhi M, et al (2012) Stimulation of glucose oxidation protects against acute myocardial infarction and reperfusion injury. Cardiovasc Res 94:359-369
11. Murthy MS, Pande SV (1984) Mechanism of carnitine acylcarnitine translocase-catalyzed import of acylcarnitines into mitochondria. J Biol Chem 259:9082-9089
12. Murthy MS, Pande SV (1987) Some differences in the properties of carnitine palmitoyltransferase activities of the mitochondrial outer and inner membranes. Biochem J 248:727-733
13. Murthy MS, Pande SV (1987) Malonyl-CoA binding site and the overt carnitine palmitoyltransferase activity reside on the opposite sides of the outer mitochondrial membrane. Proc Natl Acad Sci U S A 84:378-382
14. Ussher JR, Jaswal JS, Lopaschuk GD (2012) Pyridine nucleotide regulation of cardiac intermediary metabolism. Circ Res 111:628-641. doi: 10.1161/CIRCRESAHA.111.246371
15. Brownsey RW, Boone AN, Allard MF (1997) Actions of insulin on the mammalian heart: metabolism, pathology and biochemical mechanisms. Cardiovasc Res 34:3-24
16. Hue L, Beauloye C, Marsin AS, et al (2002) Insulin and ischemia stimulate glycolysis by acting on the same targets through different and opposing signaling pathways. J Mol Cell Cardiol 34:1091-1097
17. Hughes WA, Denton RM (1976) Incorporation of 32Pi into pyruvate dehydrogenase phosphate in mitochondria from control and insulin-treated adipose tissue. Nature 264:471-473
18. Adolfsson S, Isaksson O, Hjalmarson A (1972) Effect of insulin on glycogen synthesis and synthetase enzyme activity in the perfused rat heart. Biochim Biophys Acta 279:146-156
19. Mora A, Sakamoto K, McManus EJ, Alessi DR (2005) Role of the PDK1-PKB-GSK3 pathway in regulating glycogen synthase and glucose uptake in the heart. FEBS Lett 579: 3632-3638
20. Sidossis LS, Stuart CA, Shulman GI, et al (1996) Glucose plus insulin regulate fat oxidation by controlling the rate of fatty acid entry into the mitochondria. J Clin Invest 98:2244-2250
21. Cook GA, Gamble MS (1987) Regulation of carnitine palmitoyltransferase by insulin results in decreased activity and decreased apparent Ki values for malonyl-CoA. J Biol Chem 262:2050-2055
22. Hudson EK, Liu MH, Buja LM, McMillin JB (1995) Insulin-associated changes in carnitine palmitoyltransferase in cultured neonatal rat cardiac myocytes. J Mol Cell Cardiol 27:599-613
23. Saddik M, Gamble J, Witters LA, Lopaschuk GD (1993) Acetyl-CoA carboxylase regulation of fatty acid oxidation in the heart. J Biol Chem 268:25836-25845
24. Kudo N, Barr AJ, Barr RL, Desai S, Lopaschuk GD (1995) High rates of fatty acid oxidation during reperfusion of ischemic hearts are associated with a decrease in malonyl-CoA levels due to an increase in 5'-AMP-activated protein kinase inhibition of acetyl-CoA carboxylase. J Biol Chem 270:17513-17520
25. Dyck JR, Lopaschuk GD (2006) AMPK alterations in cardiac physiology and pathology: enemy or ally? J Physiol 574:95-112
26. Kiens B (2006) Skeletal muscle lipid metabolism in exercise and insulin resistance. Physiol Rev 86:205-243
27. Folmes CD, Clanachan AS, Lopaschuk GD (2006) Fatty acids attenuate insulin regulation of 5'-AMP-activated protein kinase and insulin cardioprotection after ischemia. Circ Res 99:61-68
28. Ruan H, Lodish HF (2003) Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha. Cytokine Growth Factor Rev 14:447-455
29. Rosen ED, Spiegelman BM (2006) Adipocytes as regulators of energy balance and glucose homeostasis. Nature 444:847-853
30. Steinberg GR, Michell BJ, van Denderen BJ, et al (2006) Tumor necrosis factor alpha-induced skeletal muscle insulin resistance involves suppression of AMP-kinase signaling. Cell Metab 4:465-474
31. Zierath JR (2007) The path to insulin resistance: paved with ceramides? Cell Metab 5:161-163
32. Pickersgill L, Litherland GJ, Greenberg AS, et al (2007) Key role for ceramides in mediating insulin resistance in human muscle cells. J Biol Chem 282(17):12583-12589
33. Evans JL, Maddux BA, Goldfine ID (2005) The molecular basis for oxidative stress-induced insulin resistance. Antioxid Redox Signal 7:1040-1052
34. Evans JL, Goldfine ID, Maddux BA, Grodsky GM (2003) Are oxidative stress-activated signaling pathways mediators of insulin resistance and beta-cell dysfunction? Diabetes 52:1-8
35. Kim JK, Gimeno RE, Higashimori T, et al (2004) Inactivation of fatty acid transport protein 1 prevents fat-induced insulin resistance in skeletal muscle. J Clin Invest 113:756-763
36. Petersen KF, Shulman GI (2006) Etiology of insulin resistance. Am J Med 119:S10-S16
37. Kahn SE, Hull RL, Utzschneider KM (2006) Mechanisms linking obesity to insulin resistance and type 2 diabetes. Nature 444:840-846
38. Dresner A, Laurent D, Marcucci M, et al (1999) Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity. J Clin Invest 103:253-259
39. Ussher JR, Lopaschuk GD (2013) Cardiac insulin resistance: it's sweeter than you think. Endocrinology 154:2575-2578
40. Paternostro G, Camici PG, Lammerstma AA, et al (1996) Cardiac and skeletal muscle insulin resistance in patients with coronary heart disease. A study with positron emission tomography. J Clin Invest 98:2094-2099
41. Utriainen T, Takala T, Luotolahti M, et al (1998) Insulin resistance characterizes glucose uptake in skeletal muscle but not in the heart in NIDDM. Diabetologia 41:555-559
42. Jagasia D, Whiting JM, Concato J, et al (2001) Effect of non-insulin-dependent diabetes mellitus on myocardial insulin responsiveness in patients with ischemic heart disease. Circulation 103:1734-1739
43. Hafstad AD, Solevag GH, Severson DL, et al (2006) Perfused hearts from Type 2 diabetic (db/db) mice show metabolic responsiveness to insulin. Am J Physiol Heart Circ Physiol 290:H1763-H1769
44. McNulty PH (2006) Metabolic responsiveness to insulin in the diabetic heart. Am J Physiol Heart Circ Physiol 290:H1749-H1751
45. Chess DJ, Stanley WC (2008) Role of diet and fuel overabundance in the development and progression of heart failure. Cardiovasc Res 79:269-278. doi: 10.1093/cvr/cvn074
46. Taegtmeyer H, Stanley WC (2011) Too much or not enough of a good thing? Cardiac glucolipotoxicity versus lipoprotection. J Mol Cell Cardiol 50:2-5
47. Zhang L, Ussher JR, Oka T, et al (2011) Cardiac diacylglycerol accumulation in high fat-fed mice is associated with impaired insulin-stimulated glucose oxidation. Cardiovasc Res 89:148-156
48. Idell-Wenger JA, Grotyohann LW, Neely JR (1978) Coenzyme A and carnitine distribution in normal and ischemic hearts. J Biol Chem 253:4310-4318
49. Bain JR, Stevens RD, Wenner BR, et al (2009) Metabolomics applied to diabetes research: moving from information to knowledge. Diabetes 58:2429-2443
50. Koves TR, Li P, An J, et al (2005) Peroxisome proliferator-activated receptor-gamma coactivator 1alpha-mediated metabolic remodeling of skeletal myocytes mimics exercise training and reverses lipid-induced mitochondrial inefficiency. J Biol Chem 280:33588-33598
51. Koves TR, Ussher JR, Noland RC, et al (2008) Mitochondrial overload and incomplete fatty acid oxidation contribute to skeletal muscle insulin resistance. Cell Metab 7:45-56
52. Keung W, Ussher JR, Jaswal JS, et al (2013) Inhibition of carnitine palmitoyltransferase-1 activity alleviates insulin resistance in diet-induced obese mice. Diabetes 62:711-720
53. Muoio DM, Noland RC, Kovalik JP, et al (2012) Muscle-specific deletion of carnitine acetyltransferase compromises glucose tolerance and metabolic flexibility. Cell Metab 15:764-777
54. Mihalik SJ, Goodpaster BH, Kelley DE, et al (2010) Increased levels of plasma acylcarnitines in obesity and type 2 diabetes and identification of a marker of glucolipotoxicity. Obesity (Silver Spring) 18:1695-1700
55. Adams SH, Hoppel CL, Lok KH, et al (2009) Plasma acylcarnitine profiles suggest incomplete long-chain fatty acid beta-oxidation and altered tricarboxylic acid cycle activity in type 2 diabetic African-American women. J Nutr 139:1073-1081
56. Kovalik JP, Slentz D, Stevens RD, et al (2011) Metabolic remodeling of human skeletal myocytes by cocultured adipocytes depends on the lipolytic state of the system. Diabetes 60:1882-1893
57. Muoio DM, Neufer PD (2012) Lipid-induced mitochondrial stress and insulin action in muscle. Cell Metab 15:595-605
58. Hirschey MD, Shimazu T, Jing E, et al (2011) SIRT3 deficiency and mitochondrial protein hyperacetylation accelerate the development of the metabolic syndrome. Mol Cell 44: 177-190
59. Jing E, O'Neill BT, Rardin MJ, et al (2013) Sirt3 regulates metabolic flexibility of skeletal muscle through reversible enzymatic deacetylation. Diabetes 62:3404-3417
60. Noland RC, Koves TR, Seiler SE, et al (2009) Carnitine insufficiency caused by aging and overnutrition compromises mitochondrial performance and metabolic control. J Biol Chem 284:22840-22852
61. Lopaschuk GD, Hansen CA, Neely JR (1986) Fatty acid metabolism in hearts containing elevated levels of CoA. Am J Physiol 250:H351-H359
62. Lopaschuk GD, Spafford MA, Davies NJ, Wall SR (1990) Glucose and palmitate oxidation in isolated working rat hearts reperfused after a period of transient global ischemia. Circ Res 66:546-553
63. Saddik M, Lopaschuk GD (1991) Myocardial triglyceride turnover and contribution to energy substrate utilization in isolated working rat hearts. J Biol Chem 266:8162-8170
64. Ussher JR, Lopaschuk GD (2008) The malonyl CoA axis as a potential target for treating ischaemic heart disease. Cardiovasc Res 79:259-268
65. Kenchaiah S, Evans JC, Levy D, et al (2002) Obesity and the risk of heart failure. N Engl J Med 347:305-313